Point72 Hong Kong’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.96M | Buy |
+132,171
| New | +$6.17M | 0.27% | 72 |
|
|
2025
Q1 | – | Sell |
-270,478
| Closed | -$15.3M | – | 491 |
|
|
2024
Q4 | $15.3M | Buy |
270,478
+246,166
| +1,013% | +$13.8M | 0.93% | 27 |
|
|
2024
Q3 | $1.26M | Sell |
24,312
-233,985
| -91% | -$11M | 0.09% | 181 |
|
|
2024
Q2 | $10.7M | Buy |
+258,297
| New | +$11.6M | 0.64% | 41 |
|
|
2024
Q1 | – | Sell |
-81,996
| Closed | -$4.21M | – | 557 |
|
|
2023
Q4 | $4.21M | Buy |
+81,996
| New | +$4.3M | 0.25% | 114 |
|
|
2022
Q3 | – | Sell |
-62,143
| Closed | -$4.51M | – | 1950 |
|
|
2022
Q2 | $4.79M | Buy |
62,143
+1,844
| +3% | +$140K | 0.18% | 148 |
|
|
2022
Q1 | $4.4M | Sell |
60,299
-8,451
| -12% | -$567K | 0.15% | 142 |
|
|
2021
Q4 | $4.29M | Buy |
68,750
+65,402
| +1,953% | +$3.84M | 0.15% | 141 |
|
|
2021
Q3 | $198K | Buy |
3,348
+2,766
| +475% | +$182K | 0.01% | 1169 |
|
|
2021
Q2 | $39K | Sell |
582
-62,763
| -99% | -$4.09M | ﹤0.01% | 1519 |
|
|
2021
Q1 | $4M | Sell |
63,345
-50,797
| -45% | -$3.16M | 0.13% | 178 |
|
|
2020
Q4 | $7.08M | Buy |
114,142
+101,340
| +792% | +$6.23M | 0.32% | 38 |
|
|
2020
Q3 | $772K | Sell |
12,802
-27,913
| -69% | -$1.68M | 0.08% | 228 |
|
|
2020
Q2 | $2.39M | Buy |
40,715
+39,086
| +2,399% | +$2.34M | 0.27% | 91 |
|
|
2020
Q1 | $91K | Sell |
1,629
-134
| -8% | -$8.19K | 0.04% | 212 |
|
|
2019
Q4 | $113K | Buy |
+1,763
| New | +$101K | 0.03% | 477 |
|
|
2019
Q3 | – | Sell |
-2,870
| Closed | -$130K | – | 1022 |
|
|
2019
Q2 | $130K | Sell |
2,870
-11,758
| -80% | -$548K | 0.04% | 429 |
|
|
2019
Q1 | $698K | Buy |
+14,628
| New | +$729K | 0.28% | 30 |
|
|
2018
Q2 | – | Sell |
-1,188
| Closed | -$75K | – | 905 |
|
|
2018
Q1 | $75K | Sell |
1,188
-189
| -14% | -$12.2K | 0.04% | 378 |
|
|
2017
Q4 | $84K | Buy |
+1,377
| New | +$86.1K | 0.06% | 141 |
|
|
2017
Q3 | – | Sell |
-3,486
| Closed | -$194K | – | 813 |
|
|
2017
Q2 | $194K | Buy |
3,486
+388
| +13% | +$21.1K | 0.2% | 40 |
|
|
2017
Q1 | $168K | Buy |
3,098
+2,754
| +801% | +$151K | 0.22% | 67 |
|
|
2016
Q4 | $20K | Buy |
+344
| New | +$18.8K | 0.02% | 549 |
|
|
2016
Q1 | – | Sell |
-100
| Closed | -$7K | – | 513 |
|
|
2015
Q4 | $7K | Buy |
+100
| New | +$6.61K | 0.02% | 310 |
|
|
2015
Q2 | – | Sell |
-5,024
| Closed | -$324K | – | 185 |
|
|
2015
Q1 | $324K | Buy |
+5,024
| New | +$315K | 0.29% | 42 |
|
Other funds holding BMY
Point72 Hong Kong's BMY Position: Q3 2025 in Review
Point72 Hong Kong opened a new position in Bristol-Myers Squibb (BMY) in Q3 2025: 132,171 shares worth $5.96M. The stake represents 0.27% of the portfolio and ranks #72 among its holdings. This is a return to the name: Point72 Hong Kong previously reported a position in BMY as recently as Q4 2024.
Point72 Hong Kong first reported a position in BMY in Q1 2015 and has held it in 25 quarters since. The position peaked at $15.3M in Q4 2024. 2,268 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Point72 Hong Kong held 132,171 shares of Bristol-Myers Squibb worth $5.96M as of Q3 2025.
- Bristol-Myers Squibb was a new Point72 Hong Kong position in Q3 2025.
- Bristol-Myers Squibb made up 0.27% of Point72 Hong Kong's portfolio in Q3 2025, its #72 holding.
- Point72 Hong Kong first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 25 quarters since.
- Point72 Hong Kong's Bristol-Myers Squibb position peaked at $15.3M in Q4 2024.
- 2,268 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.